10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: Long-term follow-up results of the randomized phase III trial AML21 of the EORTC leukemia group, GIMEMA and german MDS Study group
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Michael Lübbert, Pierre Wijermans, Michal Kicinski, Sylvain Chantepie, Walter Van der Velden, Richard Noppeney, Laimonas Griškevičius, Andreas Neubauer, Martina Crysandt, Radovan Vrhovac, Mario Luppi, Stephan Fuhrmann, Ernesta Audisio, Anna Candoni, Ollivier Legrand, Robin Foà, Gianluca Gaidano, Danielle van Lammeren-Venema, Eduardus Posthuma, Mels Hoogendoorn, Anne Giraut, Stéphanie Antunes, Marian Stevens-Kroef, Joop Jansen, Aniek De Graaf, Fabio Efficace, Emanuele Ammatuna, Jean Pierre Vilque, Ralph Wäsch, Heiko Becker, Nicole Blijlevens, Ulrich Dührsen, Frederic Baron, Stefan Suciu, Sergio Amadori, Adriano Venditti, Gerwin A. Huls
Institutions: University of Freiburg, University Medical Center Freiburg, Haga Hospital, European Organisation for Research and Treatment of Cancer, Centre Hospitalier Universitaire de Caen Normandie, Radboud University Medical Center, Krankenhaus der Barmherzigen Brüder Trier, Vilnius University, Vilnius University Hospital Santariskiu Klinikos, Philipps University of Marburg, Universitätsklinikum Aachen, RWTH Aachen University, University Hospital Centre Zagreb, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, Azienda Ospedaliera Citta' della Salute e della Scienza di Torino, Hôpital Saint-Antoine, Sapienza University of Rome, Università degli Studi del Piemonte Orientale “Amedeo Avogadro”, Reinier de Graaf Hospital, Medisch Centrum Leeuwarden, Radboud University Nijmegen, Fondazione Gimema Onlus, University Medical Center Groningen, Stiftung Universitätsmedizin Essen, University of Liège, University of Rome Tor Vergata
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417015719